摘要
目的：评价清热利湿类中药复方治疗慢性前列腺炎的疗效和安全性。方法：制定高敏感检索策略，全面检索截止2006年6月清热利湿类中药复方治疗慢性前列腺炎的临床对照研究文献，运用改良后Jadad量表评价纳入文献的方法学质量并提取有效数据进行Meta分析，用RevMan4．2软件完成统计和系统评价。结果：共44篇文献包含5746例患者符合纳入标准。3篇被评为高质量，其余为低质量。Meta分析表明，清热利湿类中药复方优于男康片（RR1．22，95％CI1．10～1．35）、舍尼通（RR1．26，95％CI1．13～1．41）；亚组分析显示，该类复方优于前列康（RR1．32，95％CI1．19～1．45）、喹诺酮类抗生素（RR1．34，95％CI1．15～1．57）；清热利湿中药对照α受体阻滞剂、普乐安片，以及清热利湿中药与合用喹诺酮类抗生素对照单用该类抗生素比较差异无显著性（P〈0．01）。18篇文献报道了不良事件的结局，未见严重不良反应的报道。结论：清热利湿类中药复方在改善慢性前列腺炎症状或体征、生活质量、前列腺液指标等可能优于男康片、舍尼通、前列康和喹诺酮类抗生素。然而，由于现有试验的方法学质量普遍较低且该类复方使用的变异性大，目前尚无足够证据支持其治疗应用，需更多高质量的随机对照试验。
Objective： To evaluate the efficacy and safety of the Qingrelishi-category Chinese medicine （for dispelling heat and resolving dampness） in the treatment of chronic prostatitis. Methods： Randomized clinical trials or controlled clinical trials comparing Qingrelishi with plant amedica, other herbal medicine and Western medicine in the treatment of chronic prostatitis were identified by electronic and manual retrieval and analysis. The methodological quality of the included trials was assessed and Meta-analysis was performed with Revman 4.2 software. Results ： Forty-four randomized clinical trials or controlled clinical trials （ n - 5 746） were identified. The methodological quality ranked high in three double-blind trials and the others ranked low. Meta-analysis indicated that Qingrelishi was more effective than Nankangpian（ RR 1.22,95% CI 1.10-1.35） and Prostat（ RR 1.26,95% CI 1.13-1.41 ） in the treatment of chronic prostatitis. Subgroup analysis revealed that Qingrelishi was more effective than Qianliekang（ RR 1.32,95% CI 1.19-1.45） and quinolones antibiotic（ RR 1.34,95% CI 1.15-1.57）. There were no significant differences in efficacy either between Qingrelishi and a-receptor blocker and Puleanpian or between Qingrelishi plus quinolone antibiotics and quinolone antibiotics alone. Eighteen articles reported side effects and no serious adverse events were reported. Conclusion： Qingrelishi may be effective in the treatment of chronic prostatitis. However, the evidence is not strong due to the generally low methodological quality and the variations of the herbs. More randomized clinical trials are required.
出处
《中华男科学杂志》
CAS
CSCD
2007年第4期370-377,共8页
National Journal of Andrology
关键词
前列腺炎
中药复方
清热利湿
系统评价
Meta分析
随机临床试验
prostatitis
compound Chinese medicine
Qingrelishi
systematic review
Meta-analysis
randomized clinical trial
